CTIS2023-504552-10-01招募中1 期
Double-blind, randomised clinical study comparing efficacy and safety of Clindamycin/Tretinoin Gel (10 mg/g + 0.25 mg/g) (Test) vs. Acnatac(R) 10 mg/g + 0.25 mg/g Gel (Reference) vs. Vehicle in patients with papulopustular acne - 23-01/ClindaTret-G
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 675
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 64（—）
- 性别
- All
入选标准
- •Women, men and adolescents of both sexes = 12 and = 65 years of age, Written consent to study participation after patient information by the investigator, In case of patients below the age of 18: Written consent to study participation of legal guardian(s) and adolescent patient after an age-appropriate patient- and legal guardian(s)- information session by the investigator, Diagnosis of papulopustular acne according to generally accepted criteria, On the face, = 25 non-inflammatory lesions (i.e. open and closed comedones) and = 20 inflammatory lesions (e.g. papules and pustules), thereof = 2 nodular lesions, Investigator`s Global Assessment (IGA) of acne severity grade 2,3 or 4, For women of childbearing potential: Application of an established highly efficient contraceptive method during the whole study, For all female patients of childbearing potential: Urine pregnancy test with negative result prior to study start. The urine pregnancy test used must have a sensitivity down at least 25 mIU/ml for human chorionic gonadotrophin (hCG) (High sensitivity pregnancy test)
排除标准
- •History or presence of Crohn`s disease, ulcerative colitis, regional enteritis, or antibiotic-associated colitis, Use within 30 days prior to baseline of: 1) spironolactone, 2) systemic glucocorticoids, 3) systemic antibiotics or 4) systemic treatment for acne vulgaris (other than oral retinoids, which require a 6-months washout), Use within 14 days prior to baseline in the face of: 1) topical steroids, 2) topical retinoids, 3) topical acne treatments including over-the-counter preparations, 4) topical anti-inflammatory agents or 5) topical antibiotics, Other severe acute or chronic concomitant disease with severe impairment of the general condition, Other concomitant diseases which may - taking the present knowledge into account - influence the parameters evaluated in the study in a way that an objective evaluation would be impossible, Other concomitant medication which may - taking the present knowledge into account - influence the methods of measurement used in this study or the resulting data, Reasonable doubt concerning the co-operation of the patient, Participation in another clinical study within the last 30 days prior to inclusion in this study, Participation in this study at an earlier date, Women with existing or intended pregnancy or during lactation, Presence of any skin condition that would interfere with the diagnosis or assessment of acne vulgaris (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell carcinoma, eczema, acneform eruptions caused by medications, steroid acne, steroid folliculitis, or bacterial folliculitis), Presence of pustular and deep cystic nodular acne lesions in the face (acne conglobata and acne fulminans), Excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere with diagnosis or assessment of acne vulgaris, Presence of skin cancer in his/her own history, Known intolerance or hypersensitivity against clindamycin, tretinoin or lincomycin or any of the other ingredients in the study medication, Use within 6 months prior to baseline of oral retinoids (e.g. isotretinoine) or therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are allowed), Use for less than 3 months prior to baseline of estrogens or oral contraceptives; use of such therapy, when taken, must remain constant throughout the study, Use on the face within 30 days prior baseline or during the study of 1) cryodestruction or chemodestruction, 2) dermabrasion, 3) photodynamic therapy, 4) acne surgery, 5) intralesional steroids, or 6) x-ray therapy
研究者
相似试验
进行中（未招募）
1 期
Clincal study to compare the therapeutic effects of two ointments with active substances betamethasone dipropionate and salicylic acid and of one ointment without active substance for patients with chronic stable plaque psoriasisEUCTR2020-004081-19-DEDermapharm AG306
进行中（未招募）
1 期
Clinical study to compare two creams with the active substance gentamicin and betamethason and one cream without active substance for patients with bacterial infected eczemaEUCTR2014-005518-44-DEDermapharm AG400
招募中
1 期
Clinical study to compare two cutaneous ointments with the active substance methylprednisolone aceponate 0.1% and one cutaneous ointment without active substance for patients with atopic dermatitisCTIS2024-514548-10-01Dermapharm AG330
进行中（未招募）
1 期
Clinical study to compare the therapeutic effects of two creams with the active substances miconazole and fluprednidene and of one cream without active substance for patients with moderate to severely inflamed infection of the skin through yeast fungi.moderate to severely inflamed candidiasis of the skinMedDRA version: 19.0Level: LLTClassification code 10007159Term: Candidiasis of skin and nailsSystem Organ Class: 100000004862EUCTR2015-005707-92-DEDermapharm AG340
招募中
1 期
Clinical study to compare two cutaneous creams with the active substance methylprednisolone aceponate 0.1% and one cutaneous cream without active substance for patients with atopic dermatitisCTIS2024-511390-30-00Dermapharm AG330